ArticleCancer immunology, immunotherapy : CII2026
Single-cell and multi-omics integration delineates the landscape of gene-wise intratumor heterogeneity and identifies prognostic biomarkers for immunotherapy in non-small cell lung cancer.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGene-wise intratumor heterogeneity (ITH), defined as spatial variability in the expression of individual genes across tumor regions, remains incompletely characterized in non-small cell lung cancer (NSCLC). Identifying low-ITH genes as predictive biomarkers offers a promising strategy to enhance the reliability of immunotherapy outcome prediction.
methodsWe profiled gene-wise ITH using multi-region scRNA-seq data and a computational framework combining variance and clustering metrics. Prognostic low-ITH genes were screened via immunotherapy RNA-seq datasets and six machine learning algorithms to construct the LITHrisk score. Transcriptomic profiling and in vitro experiments elucidated the biological and functional relevance of key score components.
resultsThe gene-wise ITH landscape in NSCLC was delineated, with several critical immune checkpoint genes, including PD-L1, LAG3, and TIM-3, being identified as low-ITH genes. A low-ITH-derived signature, the LITHrisk score (PD-L1, CDK11B, CXCL13, RPS4Y1, AKR1B10, CRLF1), effectively predicted immunotherapy prognosis and response in NSCLC and other cancers. Tumors with a low LITHrisk score were characterized by enrichment of immune response-related pathways and heightened infiltration of immune cells, such as T cells, B cells, and myeloid cells. Furthermore, we found that component genes of the score were linked to key tumor characteristics: AKR1B10 was associated with tumor immune interactions, functioning via SPP1 regulation to suppress anti-tumor immunity, while CRLF1 was implicated in promoting a fibroblast-enriched microenvironment and modulating tumor cell motility.
conclusionOur study provides a practical transcriptome-based tool for advancing precision immunotherapy and nominates potential therapeutic targets for enhancing treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.